Condition: Glomerulonephritis, IGA · Immunoglobulin A Nephropathy · Sponsor: Novartis Pharmaceuticals
A study to investigate the impact of iptacopan treatment on the underlying immunopathology in patients with IgAN by assessing changes in key clinical and molecular markers from baseline to 9 months. The study aims to provide insights into the treatment's systemic and kidney-specific aspects by quantifying the change in mesangial C3c containing fragments deposition, as an indicator of complement activation, and evaluating a variety of biomarkers related to kidney function, damage, and disease progression, including but not limited to Oxford MEST-C score.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · 1-888-669-6682 · novartis.email@novartis.com
Novartis Pharmaceuticals · +41613241111
Always discuss trial participation with your own doctor first.
| University of Alabama at Birmingham | Birmingham, Alabama, United States | Recruiting |
| UCLA Medical Center | Los Angeles, California, United States | Recruiting |
| Central Florida Kidney Specialists | Orlando, Florida, United States | Recruiting |
| Georgia Nephrology Research Inst | Lawrenceville, Georgia, United States | Recruiting |
| CaRe Research | Chubbuck, Idaho, United States | Recruiting |
| DaVita Clinical Research | Las Vegas, Nevada, United States | Recruiting |
| University Hospitals Cleveland Medical Center | Cleveland, Ohio, United States | Recruiting |
| OSU Wexner Medical Center | Columbus, Ohio, United States | Recruiting |
| Prolato Clinical Research Center | Houston, Texas, United States | Recruiting |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | CABA, Buenos Aires, Argentina | Recruiting |
| Novartis Investigative Site | Córdoba, Córdoba Province, Argentina | Recruiting |
+ 7 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06797518